GERMLINE AND TUMOR GENOMIC TESTING WITH MYRIAD

Each step. Every patient.
Exactly what you need.

You rely on specific and clinically actionable oncology test answers to ensure that each patient receives the personalized, stage-specific interventions they need. Myriad has built a comprehensive oncology-focused genetic and tumor genomic testing portfolio to do just that. Designed to empower you at each step of the cancer care continuum — from screening to treatment, from previvorship to survivorship — we provide insights you count on, with extensive patient and staff support services along the way.

View tests

Myriad Oncology™ empowers you to transform patient care

We offer a suite of services and workflow solutions designed to streamline germline and tumor genomic testing without added cost to the clinic or patient.

Accurate, useful results

  • Accurate, reliable, and actionable results to support informed decisions
  • Clear and easy-to-interpret reports for confident clinical direction
  • Lifetime commitment to variant reclassification

Unmatched customer support

  • Dedicated support team for seamless patient and provider assistance
  • Complimentary patient education with board-certified Genetic Counselors
  • Affordable testing options to ensure access for all eligible patients

Seamless efficiency

  • Fast turnaround times to meet urgent clinical needs
  • Efficient processes to reduce administrative burden and free up staff time
  • EMR integration for seamless ordering and access to results

Myriad Oncology™ empowers you to transform patient care

We offer a suite of services and workflow solutions designed to streamline germline and tumor genomic testing without added cost to the clinic or patient.

Accurate, useful results

  • Accurate, reliable, and actionable results to support informed decisions
  • Clear and easy-to-interpret reports for confident clinical direction
  • Lifetime commitment to variant reclassification

Unmatched customer support

  • Dedicated support team for seamless patient and provider assistance
  • Complimentary patient education with board-certified Genetic Counselors
  • Affordable testing options to ensure access for all eligible patients

Seamless efficiency

  • Fast turnaround times to meet urgent clinical needs
  • Efficient processes to reduce administrative burden and free up staff time
  • Expanding EMR integrations for seamless ordering and access to results of germline and tumor genomic tests

Personalize management and treatment strategies for more patients throughout their journey

Each step. High-Risk Unaffected Diagnosis
- Early stage		 Progression
- Late Stage		 Survivorship
Every Patient.
Exactly what you need.

Risk Assessment and prevention

Individualized management based on accurate hereditary cancer risk assessment

Surgery guidance

Appropriate surgery decisions based on hereditary cancer syndromes and risk of second primary cancer

Initial treatment guidance

Active surveillance and treatment intensity decisions based on guideline-supported molecular insights

Adjuvant therapy guidance

Adjuvant treatment decisions based on comprehensive guideline-supported germline and tumor genomic testing

Targeted therapy selection

FDA-approved therapies and clinical trial availability based on comprehensive germline and tumor genomic results

Management planning

Management updates and assessment of family members based on hereditary cancer syndromes

In high-risk unaffected people, the MyRisk Test detects variants associated with an increased risk for developing hereditary cancer, empowering you to personalize care plans and guide preventive treatment decisions.

The MyRisk Test with RiskScore is twice as predictive of breast cancer risk than using Tyrer-Cuzick alone, accurately stratifying five-year and lifetime risk of developing breast cancer in people of all ancestries.1

In newly diagnosed patients, The MyRisk Test identifies hereditary cancer syndromes associated with risk for a second cancer, which may inform surgical decisions.2 The MyRisk Test identifies up to 63% of variants other labs cannot definitively classify and offers the industry’s lowest reported rates of BRCA1/2 variants of uncertain significance (VUS).3,4

The Prolaris Test outperforms all other biomarkers in identifying low- and intermediate-risk patients who are suitable for active surveillance.5

The MyRisk Test identifies germline BRCA1/2 variants that may influence the use of targeted therapies, while minimizing variants of uncertain significance to expand eligibility for treatment.4,6,7

In patients with ovarian cancer, The MyChoice CDx Test helps expand access to PARP inhibitors by 34% compared to other tests that rely solely on %LOH.8

For patients diagnosed with breast cancer, the EndoPredict Test helps accurately identify those at low risk of recurrence, enabling many to avoid unnecessary chemotherapy and endocrine therapy, ensuring that only those who truly need it receive more aggressive treatment.9-11

For advanced cancer patients who have not yet received germline testing, The MyRisk Test identifies germline BRCA1/2 variants that may influence the use of targeted therapies such as PARP inhibitors.7

The Precise Tumor Test analyzes over 500 genes as well as key biomarkers, including PD-L1, to help identify comprehensive guideline-approved targeted treatment options and clinical trials, enabling tailored care for each patient.12

The MyChoice CDx Test helps ensure personalized, proactive management of recurrence and metastatic disease by determining which patients with ovarian cancer are likely to benefit from PARP inhibitors.13,14

The FOLR1/FRα test determines eligibility for mirvetuximab soravtansine-gynx in advanced ovarian cancer.

For people with a history of cancer, The MyRisk Test identifies hereditary cancer syndromes associated with an increased risk of a second cancer, providing information to guide risk management decisions and facilitate family risk assessment.15,16
Each step.
Every Patient.		 Exactly what
you need.
High-Risk Unaffected

Risk Assessment and prevention

Individualized management based on accurate hereditary cancer risk assessment

In high-risk unaffected people, the MyRisk Test detects variants associated with an increased risk for developing hereditary cancer, empowering you to personalize care plans and guide preventive treatment decisions.

The MyRisk Test with RiskScore is twice as predictive of breast cancer risk than using Tyrer-Cuzick alone, accurately stratifying five-year and lifetime risk of developing breast cancer in people of all ancestries.1

Diagnosis - Early stage

Surgery guidance

Appropriate surgery decisions based on hereditary cancer syndromes and risk of second primary cancer

In newly diagnosed patients, The MyRisk Test identifies hereditary cancer syndromes associated with risk for a second cancer, which may inform surgical decisions.2 The MyRisk Test identifies up to 63% of variants other labs cannot definitively classify and offers the industry’s lowest reported rates of BRCA1/2 variants of uncertain significance (VUS).3,4

Initial treatment guidance

Active surveillance and treatment intensity decisions based on guideline-supported molecular insights

The Prolaris Test outperforms all other biomarkers in identifying low- and intermediate-risk patients who are suitable for active surveillance.5

Adjuvant therapy guidance

Adjuvant treatment decisions based on comprehensive guideline-supported germline and tumor genomic testing

The MyRisk Test identifies germline BRCA1/2 variants that may influence the use of targeted therapies, while minimizing variants of uncertain significance to expand eligibility for treatment.4,6,7

In patients with ovarian cancer, The MyChoice CDx Test helps expand access to PARP inhibitors by 34% compared to other tests that rely solely on %LOH.8

For patients diagnosed with breast cancer, the EndoPredict Test helps accurately identify those at low risk of recurrence, enabling many to avoid unnecessary chemotherapy and endocrine therapy, ensuring that only those who truly need it receive more aggressive treatment.9-11

Progression - Late Stage

Targeted therapy selection

FDA-approved therapies and clinical trial availability based on comprehensive germline and tumor genomic results

For advanced cancer patients who have not yet received germline testing, The MyRisk Test identifies germline BRCA1/2 variants that may influence the use of targeted therapies such as PARP inhibitors.7

The Precise Tumor Test analyzes over 500 genes as well as key biomarkers, including PD-L1, to help identify comprehensive guideline-approved targeted treatment options and clinical trials, enabling tailored care for each patient.12

The MyChoice CDx Test helps ensure personalized, proactive management of recurrence and metastatic disease by determining which patients with ovarian cancer are likely to benefit from PARP inhibitors.13,14

The FOLR1/FRα test determines eligibility for mirvetuximab soravtansine-gynx in advanced ovarian cancer.
Survivorship

Management planning

Management updates and assessment of family members based on hereditary cancer syndromes

For people with a history of cancer, The MyRisk Test identifies hereditary cancer syndromes associated with an increased risk of a second cancer, providing information to guide risk management decisions and facilitate family risk assessment.15,16

Guidelines affirm the importance of germline and tumor genomic testing

While tumor genomic testing has long been recommended for patients with metastatic or advanced cancers, the American Society of Clinical Oncology (ASCO) supports the expansion of multigene germline testing to better ensure eligible patients and their families receive optimal care.7

  • ASCO advises germline testing for patients who meet guidelines regardless of their tumor results, to ensure comprehensive detection of pathogenic variants and optimized treatment planning7
  • The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend germline testing in the workup for patients diagnosed with, or after confirmation of, ovarian, breast, pancreatic, prostate, and colon cancer1,2
  • All patients with breast cancer meet criteria for germline genetic testing regardless of family history or age17

Did you know? The MyRisk Test is the most actionable and guideline-driven commercially available multigene core panel:2,7,18

  • Focusing exclusively on genes backed by rigorous clinical evidence and cited in national oncology guidelines
  • Ensuring no relevant findings are missed
  • Helping to avoid the uncertainty associated with non-actionable results

Image of Carol, a Myriad Oncology female patient

Meet Carol, a patient empowered through Myriad Oncology portfolio of genetic tests image

Streamlined germline and tumor genomic testing

Ordering both germline and tumor genomic testing from Myriad ensures consolidated and concordant results at each step, empowering you to deliver a truly personalized treatment strategy for each patient.

With Myriad, you will benefit from a streamlined experience for obtaining consolidated germline and tumor genomic results:

  • A guideline-aligned testing approach supports clinical decisions by incorporating comprehensive germline and tumor genomic testing
  • Consolidated germline and tumor genomic results are available within 14 days
  • Dedicated support team for seamless patient and provider assistance
  • Streamlined germline and tumor genomic results in one cohesive report, including a simple summary of key findings for all tests ordered in one sheet

The comprehensive Myriad Oncology portfolio of germline and tumor genomic tests are now integrated into the OncoEMR® system for fewer steps, even faster turnaround, and greater impact on patient care.

A partner to you and your patients

Myriad has invested over 30 years into developing tests and solutions that help you, your patients, and your practice by providing the best answers and care possible. See how we can help streamline your patient care:

Helpful tools to quickly identify patients who meet criteria for germline testing based on guidelines

Point of care pre-test education sessions with a board-certified Genetic Counselor, including documented case notes

Easy ordering options including paper, online, virtual, and EMR for seamless ordering and access to results

Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay

Tissue specialists ensure tumor tissue is quickly processed, and any unused tissue is promptly returned to the pathology lab

Consolidated germline and tumor genomic results are typically available within 14 days

Treatment-focused reporting streamlines germline and tumor genomic results into an easy-to-follow report

Medical Science Liasons support you and your team in addressing clinical, testing, and results-related questions

Post-test results consults with board-certified Genetic Counselors can be scheduled or are available on demand

Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a VUS is reclassified as clinically significant

Get started with Myriad Oncology

Request more information from our team or explore ordering options and resources to bring Myriad Oncology testing into your practice.

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Contact Information

Myriad Oncology resources

0

Webinars and Events

Explore upcoming webinars and events featuring the latest advancements in germline and tumor genomic testing, presented by Myriad medical experts and special guest speakers. Register now to reserve your spot and browse recordings of past sessions.

Learn more
0

Latest studies & publications

Stay current with clinical validation and utility publications and more.

Learn more
0

Documents & forms

Find the Myriad documents and forms you need right here.

Learn more

References:

  1. Mabey B, Hughes E, Kucera M, et al. Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. Genet Med. 2024;26(7):101128.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines.) Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V1.2026. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 4, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  3. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  4. Mundt E, McGreevy K, Nix P, Cummings S. Myriad’s Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025.
  5. Hu JC, Tosoian JJ, Qi J, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precis Oncol. 2018;2:PO.18.00163.
  6. Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next-generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.
  7. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  8. Mills GB, Timms KM, Perry M, et al. Comparison of Genomic Instability Scores for Predicting PARP Activity in Ovarian Cancer. Poster presented at the 2020 SGO Annual Meeting on Women’s Cancer.
  9. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
  10. Filipits M, Sestak I, Buus R, et al. Prediction of distant recurrence using EndoPredict among women with ER+, HER2− node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res. 2019;25(13):3865-3872.
  11. Sestak I, Martín M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019;176(2):377-386.
  12. Conroy JM, Pabla S, Glenn ST, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One. 2021;16(12):e0260089.
  13. Tew WP, Lacchetti C, Birrer MJ, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468-3493.
  14. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022;40(11):1231-1258.
  15. Sadik H, Pritchard D, Keeling DM, et al. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022;6:e2200246.
  16. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025-3031.
  17. The American Society of Breast Surgeons. Consensus guidelines on genetic testing for hereditary breast cancer. 2019.
  18. Internal product development data on file at Myriad Genetics, Inc. Last updated 2025.

©2025 Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific. Eurobio Scientific has licensed the EndoPredict test to Myriad Genetics in select territories.

Locations

United States
Europe
Japan